Retinal Vein Occlusion (RVO) Medication

Updated: Sep 20, 2019
  • Author: Jesse Borke, MD, FACEP, FAAEM; Chief Editor: Gregory Sugalski, MD  more...
  • Print

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and prevent complications.



Class Summary

These agents have anti-inflammatory properties and cause profound and varied metabolic effects. In addition, these agents modify the body's immune response to diverse stimuli.

Triamcinolone (Triesence)

Useful in treatment of inflammatory and autoimmune reactions. By reversing increased capillary permeability and suppressing PMN activity, it may decrease inflammation.

Dexamethasone intravitreal implant (Ozurdex)

Corticosteroids suppress inflammation by inhibiting multiple inflammatory cytokines, resulting in decreased edema, fibrin deposition, capillary leakage, and migration of inflammatory cells. Indicated for treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion.


Vascular Endothelial Growth Factor (VEGF) Inhibitors

Class Summary

Agents in this class are used to suppress neovascularization and to slow vision loss.

Ranibizumab (Lucentis)

Ranibizumab inhibits angiogenesis by targeting and inhibiting vascular endothelial growth factor (VEGF). Inhibiting new blood vessel formation denies blood, oxygen, and other nutrients needed for the development of new blood vessels.